Our COVID-19 Testing

DIAGNOSTIC TESTING

DIAGNOSTIC
SARS-CoV-2 Diagnostic Respiratory PCR Test
Learn more
  • Diagnostic test for SARS-CoV-2, using real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology
  • Detects the presence of SARS-CoV-2 viral RNA in respiratory samples • Determines current SARS-CoV-2 infection but does not indicate past infection or immunity
  • Utilizes Nasal or Nasopharyngeal swab
  • Additional collection services are required (cost is included in the price)
  • Rapid 24-48 hour turnaround time

Pros

  • Utilizes Nasal or Nasopharyngeal swab
  • Additional collection services are required (cost is included in the price)
  • Rapid 24-48 hour turnaround time Video Overview
DIAGNOSTIC
SARS-CoV-2 Diagnostic Salivary PCR Test
Learn more
  • Diagnostic test for SARS-CoV-2, using real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology
  • Detects the presence of SARS-CoV-2 viral RNA in salivary samples
  • Determines current SARS-CoV-2 infection but does not indicate past infection or immunity
  • Utilizes simple at-home salivary collection
  • No additional collection services are required
  • Rapid 24-48 hour turnaround time
DIAGNOSTIC
Flowflex COVID-19 Antigen Home Test
Learn more
Temporarily Out of Stock

A rapid test for the detection of COVID-19 antigens in nasal swab specimens.

  • Easy to Use
  • Accurate
  • Quick Results
DIAGNOSTIC
Quidel Quickvue At Home OTC COVID-19 Tests
Learn more

This item is packaged as 1 bulk box that contains 25 single tests in a kit.

The QuickVue At-Home OTC COVID-19 Test is intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 36 hours between tests. This test is authorized for nonprescription home use with self-collected (unobserved) direct anterior nasal (NS) swab specimens from individuals aged 14 years and older or with adult-collected anterior NS samples from individuals aged 2 years or older.

The QuickVue At-Home OTC COVID-19 Test does not differentiate between SARS-CoV and SARS-CoV-2.

SURVEILLANCE TESTING

SURVEILLANCE
COVID-19 Immune Response Panel
Learn more

Serum test that measures both nucleocapsid (N-protein) and S-RBD antibodies

The COVID-19 Immune Response Panel measures both nucleocapsid (N-protein) and S-RBD antibodies. N-protein antibodies do not rise in response to COVID-19 S-RBD vaccinations. The combined serum IgM/IgG tests measure the body’s response to COVID-19 nucleocapsid (N) and spike protein receptor-binding domain (S-RBD) exposure. The N and S-RBD antibodies’ combination assay has a > 99% positive and negative predictive value 15 days after COVID-19 exposure. This test does not differentiate between IgM and IgG; studies indicate that joint testing is as or more reliable than individual IgM and IgG testing in confirming COVID-19 exposure.

SURVEILLANCE
COVID-19 Vaccine Response Screen
Learn more

Serum test which measures only the antibody response to the S-RBD protein

The COVID-19 Vaccine Response Screen measures only the antibody response to the S-RBD protein. Once the baseline immune response has been established, this test can be used post-vaccination to evaluate immune status. The average time for seroconversion has been estimated at 2-3 weeks. However, the strongest antibody responses will likely be seen after the second vaccine dose 6-8 weeks after the first inoculation.

SURVEILLANCE
SARS-CoV-2 Quantitative IgG+IgM Antibody Panel
Learn more

COVID-19 antibody testing utilizes a serum sample to identify exposure to the SARS-CoV-2 virus, regardless of symptom presentation. The COVID-19 IgG + IgM Antibody Panel evaluates IgG and IgM reactivity separately, providing individual results for each. This may be useful for determining the current stage of infection.

This test is performed on a high-precision chemiluminescent immunoassay that has received FDA authorization under emergency use authorization (EUA).

In a human study of COVID-19 patients, the COVID-19 IgG + IgM Antibody Panel was found to meet the following specifications for sensitivity and clinical specificity:

IgG:

  • 100% Sensitivity
  • 97.4% Specificity
  • @ >15 days post-infection

IgM:

  • 94.4% Sensitivity
  • 98.3% Specificity
  • @ >15 days post-infection